A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
Saved in:
| Title: | A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. |
|---|---|
| Authors: | Malhotra J; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey. Electronic address: jm1940@cinj.rutgers.edu., Nikolinakos P; Hematology and Medical Oncology, University Cancer & Blood Center, Athens, Georgia., Leal T; Hematology-Oncology, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Lehman J; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Morgensztern D; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri., Patel JD; Department of Medicine (Oncology), Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Wrangle JM; Department of Medicine, Medical University of South Carolina, Charleston, South Carolina., Curigliano G; Division of Early Drug Development for Innovative Therapy, Istituto Europeo di Oncologia, IRCCS, Milano, Italy; Department of Oncology and Haematology, University of Milano, Milano, Italy., Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Hôpital de la Timone, Aix Marseille University, Marseille, France., Johnson ML; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, Tennessee., Ready N; Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina., Robinet G; Service de Pneumologie, CHU de Brest-Hôpital Morvan, Brest, France., Lally S; AbbVie Stemcentrx, South San Francisco, California., Maag D; AbbVie Inc., Chicago, Illinois., Valenzuela R; AbbVie Stemcentrx, South San Francisco, California., Blot V; AbbVie Inc., Chicago, Illinois., Besse B; Gustave Roussy, Villejuif, France; Espace Technologique, Paris-Saclay University, Saint-Aubin, France. |
| Source: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Sep; Vol. 16 (9), pp. 1559-1569. Date of Electronic Publication: 2021 Feb 27. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
